Myriad Genetics Marking Prostate Cancer Awareness Month with Hereditary Testing Outreach

Myriad Genetics Marking Prostate Cancer Awareness Month with Hereditary Testing Outreach
Myriad Genetics is marking Prostate Cancer Awareness Month by highlighting the importance of assessing the hereditary risk of the disease. The company is using its myRisk Hereditary Cancer test in its public outreach effort in September. The tool identifies mutations in men diagnosed with prostate cancer. Myriad develops and commercializes molecular diagnostic tests that can determine the risk of developing a disease, assess the risk of it progressing, and guide patients' treatment decisions. The myRisk test looks for 28 genes associated with eight hereditary types of cancer, including prostate cancer, to assess hereditary cancer risk. In its two decades of molecular diagnostics work, Myriad has tested more than 2.7 million people. "We are proud to be leaders in the field of prostate cancer, and myRisk is an excellent complement to our existing prostate cancer prognostic test, Prolaris, to further enhance physicians' ability to individualize care for patients with prostate cancer," Jonathan Lancaster, Myriad's chief medical officer, said in a press release. “We are pleased to bring myRisk's quality and accuracy in prostate cancer genetics to physicians who are working tirelessly to help patients and their children protect their health in the future." Men with prostate c
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *